PDSB Quote, Financials, Valuation and Earnings

Cocrystal Pharma has a net margin of -- compared to PDS Biotechnology's net margin of --. PDS Biotechnology's return on equity of -- beat Cocrystal Pharma's return on equity of --.

PDS Biotechnology has a consensus price target of $8.13, signalling upside risk potential of 544.84%. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 463.06%. Given that PDS Biotechnology has higher upside potential than Cocrystal Pharma, analysts believe PDS Biotechnology is more attractive than Cocrystal Pharma.

PDS Biotechnology has a beta of 1.676, which suggesting that the stock is 67.622% more volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.347, suggesting its more volatile than the S&P 500 by 134.714%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than Cocrystal Pharma quarterly revenues of --. PDS Biotechnology's net income of -$10.7M is lower than Cocrystal Pharma's net income of -$4.9M. Notably, PDS Biotechnology's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus 7.49x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to PDS Biotechnology's net margin of -49.65%. PDS Biotechnology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

PDS Biotechnology has a consensus price target of $8.13, signalling upside risk potential of 544.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.8%. Given that PDS Biotechnology has higher upside potential than NovaBay Pharmaceuticals, analysts believe PDS Biotechnology is more attractive than NovaBay Pharmaceuticals.

PDS Biotechnology has a beta of 1.676, which suggesting that the stock is 67.622% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.363%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. PDS Biotechnology's net income of -$10.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, PDS Biotechnology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rafarma Pharmaceuticals has a net margin of -- compared to PDS Biotechnology's net margin of --. PDS Biotechnology's return on equity of -- beat Rafarma Pharmaceuticals's return on equity of --.

PDS Biotechnology has a consensus price target of $8.13, signalling upside risk potential of 544.84%. On the other hand Rafarma Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that PDS Biotechnology has higher upside potential than Rafarma Pharmaceuticals, analysts believe PDS Biotechnology is more attractive than Rafarma Pharmaceuticals.

PDS Biotechnology has a beta of 1.676, which suggesting that the stock is 67.622% more volatile than S&P 500. In comparison Rafarma Pharmaceuticals has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.411%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rafarma Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. Rafarma Pharmaceuticals pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than Rafarma Pharmaceuticals quarterly revenues of --. PDS Biotechnology's net income of -$10.7M is higher than Rafarma Pharmaceuticals's net income of --. Notably, PDS Biotechnology's price-to-earnings ratio is -- while Rafarma Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus -- for Rafarma Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -- compared to PDS Biotechnology's net margin of -856.24%. PDS Biotechnology's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -138.47%.

PDS Biotechnology has a consensus price target of $8.13, signalling upside risk potential of 544.84%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $406.67 which suggests that it could grow by 1424.81%. Given that Tonix Pharmaceuticals Holding has higher upside potential than PDS Biotechnology, analysts believe Tonix Pharmaceuticals Holding is more attractive than PDS Biotechnology.

PDS Biotechnology has a beta of 1.676, which suggesting that the stock is 67.622% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.226, suggesting its more volatile than the S&P 500 by 122.624%.

PDS Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

PDS Biotechnology quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.6M. PDS Biotechnology's net income of -$10.7M is higher than Tonix Pharmaceuticals Holding's net income of -$22.1M. Notably, PDS Biotechnology's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology is -- versus 3.35x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.